Slow-release lanreotide in the treatment of acromegaly: A study in 66 patients

European Journal of Endocrinology

Volumn 143, Issue 5, 2000, Pages 577-584

  Verhelst, J A ^a   Pedroncelli, A M ^a   Abs, R ^a   Montini, M ^a   Vandeweghe, M ^a   Albani, G ^a   Maiter, D ^a   Pagani, M D ^a   Legros, J J ^a   Gianola, D ^a   Bex, M ^a   Poppe, K ^a   Mockel, J ^a   Pagani, G ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HORMONE DETERMINATION; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; PRIORITY JOURNAL; SCORING SYSTEM; SLOW DRUG RELEASE; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; TUMOR VOLUME; VERTIGO;

EID: 0033672781     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430577     Document Type: Article

References (29)

1. Recent advances in pathogenesis, diagnosis, and management of acromegaly
2. An audit of outcome of treatment in acromegaly
3. Acromegaly
4. Confusion in clinical laboratroy GH and IGF-I reports
5. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurements in acromegaly
6. Surgical management of acromegaly
7. Radiation therapy of acromegaly
8. Treatment of acromegaly with dopamine agonists
9. Cabergoline in the treatment of acromegaly: A study in 64 patients
10. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine
11. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects
12. Long-term treatment of 189 acromegalic patients with the somatostatin analog, octreotide. Results of the International Multicentre Acromegaly Study Group
13. Octreotide treatment of acromegaly. A randomized, multicentre study
14. Sandostatin LAR in acromegalic patients: Long term treatment
15. Results of a European multicentre study with sandostatin LAR in acromegalic patients
16. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly
17. Pharmacokinetics and efficacy of the long-acting somatostatin analogue, somatuline, in acromegaly
18. Long-term treatment of acromegaly with the slow release somatostatin analogue, lanreotide
19. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
20. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide
21. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
22. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study
23. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
24. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
25. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide
26. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study
27. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
28. Medical therapy for acromegaly
29. Safety and efficacy of long-term octreotide therapy for acromegaly: Results of a multi-center trial in 103 patients